UnknownNot Applicable

Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris

Egypt50 participantsStarted 2022-05-01

Plain-language summary

This study aims to assess the expression of SCCA2 in the skin of patients with warts and to detect its correlation with characteristics of warts.

Who can participate

Age range1 Year

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients present with warts (verruca vulgaris type). Exclusion Criteria: * Subjects who presenting with allergic diseases or other dermatological diseases or had a history of squamous cell carcinoma will be excluded from this study.

What they're measuring

Assessment of Squamous Cell Carcinoma Antigen2 in Verruca Vulgaris

Timeframe: through study completion, an average of 1 year

Trial details

NCT IDNCT05409365

SponsorSohag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-11-01

Contact for this trial

Fatma Aboelmgd Abd-Elgaber, Resident

01021708589 fatma011124@med.sohag.edu.eg

View on ClinicalTrials.gov More Verruca Vulgaris trials